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Abstract
The routine use of genomic sequencing in clinical medicine has the potential to dramatically alter
patient care and medical outcomes. To fully understand the psychosocial and behavioral impact of
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sequencing integration into clinical practice, it is imperative that we identify the factors that
influence sequencing-related decision making and patient outcomes. In an effort to develop a
collaborative and conceptually grounded approach to studying sequencing adoption, members of
the National Human Genome Research Institute's Clinical Sequencing Exploratory Research
Consortium formed the Outcomes and Measures Working Group. Here we highlight the priority
areas of investigation and psychosocial and behavioral outcomes identified by the Working Group.
We also review some of the anticipated challenges to measurement in social and behavioral
research related to genomic sequencing; opportunities for instrument development; and the
importance of qualitative, quantitative, and mixed-method approaches. This work represents the
early, shared efforts of multiple research teams as we strive to understand individuals' experiences
with genomic sequencing. The resulting body of knowledge will guide recommendations for the
optimal use of sequencing in clinical practice.
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The dramatic reduction in the cost of genomic sequencing coupled with the improved
accuracy of genomic technologies has set the stage for routine use of whole-exome and
whole-genome sequencing in medical care. Although sequencing holds the potential to
improve patient outcomes, models for the optimal delivery of genomic care are lacking. To
systematically investigate the impact of sequencing integration on individuals and health
systems, and to foster collaboration in research on the major ethical, legal, and social
implications of sequencing technologies, the National Human Genome Research Institute
(NHGRI) formed the Clinical Sequencing Exploratory Research (CSER) Consortium. A
principal challenge faced by CSER investigators is the need to accurately measure the
factors that influence sequencing-related decision making and outcomes. To that end,
investigators formed the Outcomes and Measures Working Group to harmonize some of the
patient-centered outcome measures that will be used in CSER projects, provide a forum for
discussing development of novel measures, and facilitate cross-study, data-driven analyses.
Trough an iterative process, we have identified and shared knowledge about measures that
are in the public domain and discussed the pros and cons of outcome measurement in a
variety of areas. In some cases, we have reached consensus on the measures that might be
appropriate for use across our diverse study settings and populations. Although our group
has identified many high-priority domains for investigation (Figure 1), we do not endorse
specific measures. In this article, we outline priority areas for ethical, legal, and social
implications research that working group members have identified to date. Although some
CSER sites are also investigating provider perspectives on sequencing, that work will not be
the focus of this article. Rather, this research agenda serves as a first step in the development
of a collaborative and conceptually grounded approach to studying participant outcomes in
anticipation of future widespread sequencing adoption.
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Overview of the CSER Consortium
The projects in the CSER Consortium investigate a diverse set of research questions in a
variety of clinical and research contexts (Supplementary Table S1 online). Briefly, the
CSER Consortium includes projects funded through multiple mechanisms by the NHGRI,
including U01 projects (RFA-HG-10–017), R01 projects (RFA-HG-11-003), R21 projects
(RFA-HG-11-004), and investigator-initiated grants, as well as an NHGRI Intramural
sequencing study. The U01 projects evaluate the integration of genomic sequencing in the
clinical care of healthy individuals and adults with cardiomyopathy (Brigham and Women's
MedSeq); in adults with metastatic lung and colon cancer (Dana-Farber Cancer Institute/
Broad CanSeq); in adults who have clinical indications for testing for colorectal cancer/
polyposis (University of Washington); in adults with cancer and cardiac disorders, children
with dysmorphic findings, and adults and children with neurological disorders (University of
North Carolina); in pediatric cancer patients (Baylor College of Medicine); and in children
with heterogeneous disorders (Children's Hospital of Philadelphia). The investigators of the
R01, R21, and investigator-initiated projects are studying issues related to the moral (The
Children's Mercy Hospital) and legal duty to return sequencing research results (in pediatrics
at Vanderbilt University and in newborn screening at Johns Hopkins University); the
standards for sequencing-related informed consent (Columbia University); research
participants' preferences for the return of research sequencing results (Seattle Children's
Hospital, Columbia University, and Boston Children's Hospital); strategies for offering
incidental findings to biobank research participants and deceased research participants'
family members (University of California, San Francisco/Mayo Clinic/University of
Minnesota); and attitudes and beliefs of patients and genetics professionals regarding the
return of diagnostic genomic findings (Case Western Reserve University). The NHGRI
Intramural program funds sequencing research on well-phenotyped adults (ClinSeq).
Although the NHGRI has recently funded additional clinical sequencing U01 sites that are
now part of the Consortium, investigators from those projects were not involved in the early
work of the Outcomes and Measures Working Group that is detailed in this article.
Domains of Interest and Measurement of Impact
The Outcomes and Measures Working Group identified six major domains for coordination
(Table 1). We considered a number of key factors when evaluating the domains for
coordination, including whether the domains (i) are included in health decision-making or
health behavior models that are being used at individual CSER sites, (ii) are being evaluated
by at least two CSER projects, (iii) are the subject of prior genomics work, and (iv) were
identified through clinical observation. For each area, we have identified compelling reasons
for inclusion of the domain in Consortium studies, a brief overview of the published
literature, a general description of how Consortium projects are addressing the domain, and
challenges to domain measurement. Importantly, we recognize that measuring the impact of
genomic sequencing is dependent on study design. Experimental designs—i.e., randomized
controlled trials comparing patients who receive genomic sequencing with those who do not
—may disentangle the effect of potential confounding factors. Observational studies (i.e.,
non–randomized controlled trials) may provide more descriptive data about the impact of
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genomic sequencing on individuals. Both study designs have advantages and disadvantages
and are represented across the various projects in the Consortium.
Conceptual Domains
Preferences for information
There is much debate about what role patient preferences should play in the disclosure of
genomic sequencing results. When asked hypothetically, most patients and research
participants express interest in receiving all types of results, even those of uncertain
signifcance.1 Facio et al.1 reported that 95% of participants in the NHGRI ClinSeq study
wished to learn results from whole-genome sequencing and that intentions to learn results
were higher for actionable findings and carrier status as compared with nonactionable
findings and uncertain genomic results.1 However, despite this general enthusiasm, the
uptake of clinical genetic testing in the setting of single-gene studies in some cases is
considerably lower,2,3 suggesting that a subset of at-risk individuals hesitate to receive
genetic information. Evidence from decision-making research demonstrates that intentions
predict only a subset of health-related behaviors.4 In addition, genetic testing uptake may be
influenced by factors such as access to testing, insurance coverage, and provider
knowledge.2
In July 2013, the American College of Medical Genetics and Genomics issued a
recommendation that all laboratories conducting genomic sequencing seek out pathogenic or
likely pathogenic variants in 56 genes associated with actionable conditions and that the
results be disclosed to the ordering physician, irrespective of patient preferences.5 These
recommendations have generated substantial controversy. Although some Consortium
projects do not rely on individual preferences to inform decisions about the return of results,
others are specifically designed to assess and accommodate individual preferences.
A principal challenge in measuring preferences, whether hypothetically or in the context of
actual decision making, is that there are few validated measures of preferences for the
disclosure of genomic findings. Broader measures of preferences for shared decision
making, such as the Shared Decision Making Questionnaire6 and the Control Preference
Scale,7 provide insight into what roles participants would like to play in decisions about the
communication of genetic test information. However, many projects are developing novel
preference measures, posing questions about individuals' desires for information categorized
according to key attributes (e.g., actionable versus nonactionable) and/or medical indications
(e.g., pharmacogenomics, disease risk alleles). Qualitative methods can provide a nuanced
understanding of individual preferences, by allowing investigators to probe participants on
how they understand constructs such as actionability and uncertainty. Finally, many
Consortium studies have decided that it is important to assess preferences for results both
pre- and postdisclosure, in order to assess the stability of individual preferences over time
and to determine the impact of disclosure on preference stability.
Participant understanding: cognitive and emotional processing of sequencing findings
The Working Group devoted considerable attention to the challenges of measuring how
individuals understand and process information in the context of sequencing.
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“Understanding” in the setting of genomic sequencing can be conceptualized in many ways
and assessed at multiple points in the testing process. Furthermore, there is a lack of
consensus across CSER sites about how understanding should be defined and
operationalized. Although assessment of baseline understanding (e.g., genetic knowledge),
understanding after an informed consent session, and understanding of the limitations of
sequencing technologies are essential—and are therefore key independent variables in a
number of projects—we focus the present discussion on the understanding of disclosed
sequencing results (e.g., health implications of testing). Accurately measuring how
individuals process and understand disclosed sequencing information is imperative because
it allows us to evaluate the adequacy of existing systems for the return of genomic findings.
Prior studies have assessed individuals' knowledge, risk perception, and information recall
in the setting of genetic testing. Disclosure of genetic test results can lead to more accurate
risk perception and increased knowledge.8 Moreover, a study of multiplex genetic
susceptibility testing concluded that patients commonly recall test results correctly and do
not interpret test results in overly deterministic ways.9 Yet disclosure may also be associated
with misinterpretation and confusion. For example, individuals who receive “negative”
results can underestimate their risk to pass a condition onto a child,10 and individuals who
are informed that they have variants of unknown significance or intermediate-risk alleles
may have difficulty understanding and interpreting their results.10–12 Individuals can also
maintain pretesting risk perceptions, even when they understand the implications of genomic
test results. For example, a study of APOE testing for Alzheimer disease risk showed that a
subset of research participants accurately recalled their testing-based risk but still believed
that their risk was either higher or lower than the risk provided by the study team.13
Measuring how individuals understand and process disclosed genomic sequencing
information is challenging for several reasons. First, sequencing results vary in terms of
actionability, predictive value, and potential impact.14 Measurement of understanding and
information processing may be complicated by the fact that individuals often receive
multiple results simultaneously and that the implications of each result may differ. In
addition, there are different ways to assess accurate understanding. For example, should the
gold standard for understanding be concordance between the person who disclosed the
findings and the person whose DNA was sequenced? Should we measure the degree of
understanding by asking individuals to report the health implications of testing and compare
their answers to relevant data in expertly curated genomic databases? Is it enough that
individuals accurately recall the information that was given to them, or should they also
appreciate the personal relevance of the information? What weight should be given to
subjective understanding (i.e., how well the individual believes he/she understands the
information)?15
Projects in the CSER Consortium are measuring understanding, information processing, and
affective response in a variety of ways. There are a few validated knowledge measures that
are being adapted by some CSER Consortium projects, including a knowledge of
sequencing scale developed by Kaphingst16 in conjunction with ClinSeq colleagues.9 Some
sites have adapted a previously published measure of subjective understanding developed by
Joffe et al.15 Given the fact that emotion plays an extremely important role in information
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processing and decision making,17,18 a number of sites are also using measures that include
an assessment of affective outcomes such as anticipated regret and tolerance of uncertainty.
The ClinSeq group is developing a novel measure of uncertainty, specific to genomic
sequencing, that also includes an assessment of affective outcomes. Given the lack of
standardization and complexities in defining and measuring postdisclosure understanding,
however, the majority of projects have developed novel scales and are using qualitative
methods (e.g., discourse analysis of disclosure visits, postdisclosure patient interviews) to
explore the different ways individuals process and make meaning of information. These
methods may help lay the groundwork for future measure development.
Psychological responses to the return of results
Research consistently shows that individuals generally experience minimal adverse
psychological sequelae after receipt of genetic risk information. Even among individuals
receiving results indicating increased disease susceptibility, most studies have shown either
no change or a decrease in negative emotions such as anxiety and depression as compared
with prereturn levels. These patterns are seen both in testing for conditions with no
preventive options, such as Huntington disease, and in testing for conditions with preventive
options, such as melanoma.19,20 Similarly, most individuals have benign emotional
responses to single-nucleotide polymorphism analyses, providing genetic risk information
about multiple conditions simultaneously.21 A possible exception to this general principle
may occur among individuals with elevated psychological distress at baseline (representing
a potentially more vulnerable group) and among certain individuals affected by disease as
compared with healthy individuals.22–24
Although findings from prior work in the setting of single-gene and single-nucleotide
polymorphism testing are generally reassuring, the effects of returning genomic sequencing
results, particularly in a clinical context, are unexplored. Responses to the return of sequence
results may differ for several reasons. First, genomic sequencing can provide huge quantities
of unexpected risk information about a vast array of diseases. It may also provide
information that is qualitatively different from susceptibility information, such as findings
related to pharmacogenomics or ancestry. In other contexts, the disclosure of unexpected
information has produced anxiety in some populations.25
Second, uncertainty pervades genomic sequencing information. Sequencing has the potential
to introduce uncertainty not only about the probability of illness through the disclosure of
known risk variants but also about whether specific variants are actually associated with
disease risk at all (variants of uncertain significance).26 Unlike previous sources of genetic
risk information, sequencing further introduces the complexity of uncertainty in
disentangling gene–gene interactions and gene–environment interactions that lead to disease
risk. Helping patients to understand these sources of uncertainty will be critical to managing
expectations about sequencing information. To this end, ClinSeq investigators have
developed and validated a novel scale of perceptions of uncertainty related to genomic
sequencing that includes three subscales: medical, affective, and trustworthiness.
Convergent and divergent validity data using measures of resilience and ambiguity aversion
support hypothesized relationships. Publication of the scale is underway. Prior research
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suggests that providers may interpret uncertainty differently than do patients.27 Thus,
effective communication will entail assessing perceptions of uncertainty to maximize
understanding and minimize the negative impacts of uncertain information. Supplementary
Table S2 online details some of the specific questions related to psychological outcomes that
the CSER Consortium is positioned to address.
Numerous well-validated scales that assess emotional states and traits, including depression
and anxiety, have been used in research on genetic testing.17 The majority of Consortium
studies are using scales such as the 9-item Patient Health Questionnaire28 to measure
depression, the 7-item General Anxiety Disorder scale29 to measure anxiety, or the 14-item
Hospital and Depression Scale30 to measure both. In addition, well-established scales to
measure more encompassing constructs such as quality of life and happiness may be more
appropriate for specific studies.
Identifying sensitive instruments that focus specifically on psychological responses to
genetic information has been more challenging. Although a number of scales have been
developed and tailored for BRCA testing,31 Lynch syndrome testing,32 and APOE
genotyping for Alzheimer disease risk,33 the Consortium has focused on two that can be
adapted more easily to the disclosure of sequencing results. The first is the Psychological
Adaptation to Genetic Information Scale,34 a 26-item instrument that assesses frequency of
intrusive thoughts, ability to discuss results with others, self-worth, certainty about
information, and perceived control over consequences of genetic information. The second is
the Multidimensional Impact of Cancer Risk Assessment scale,35 a 25-item instrument
assessing distress, uncertainty, and positive responses to genetic test results for cancer risk.
Although both scales enhance the ability to examine the impact of specific information and
more nuanced outcomes, each has limitations. Disadvantages of the Psychological
Adaptation to Genetic Information Scale are limited use to date and an initial focus on
single-gene testing, whereas disadvantages of the Multidimensional Impact of Cancer Risk
Assessment include limited use outside of testing for cancer risk, focus on single-gene
testing, and questionable internal consistency on subscales in some studies.36,37 Examining
the performance of well-adapted versions of each of these scales in the CSER Consortium
will provide valuable guidance for future research.
Adaptation of these scales also raises important conceptual questions. First, what impact are
researchers trying to assess? Is it the impact of information disclosure generally or of
disclosure of specific results? Second, in the latter case, how should psychological impact be
measured when multiple results, and/or results that have implications for both the individual
and his/her family, are returned? The Psychological Adaptation to Genetic Information
Scale and Multidimensional Impact of Cancer Risk Assessment were developed for testing
specific genes and thus provide results that can be more easily categorized as “mutation
positive,” “mutation negative,” and “indeterminate.” More complex results may require
broader conceptualization of potential responses. Third, when is the appropriate time to
measure psychological responses? Data from targeted testing performed on largely self-
selected populations have generally shown the emotional impact of test results to be
transient.38–40 In situations such as when sequencing is being used to inform cancer care,
individuals may not be able to appreciate the implications of sequencing results until
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treatments have been completed. Conversely, the emotional impact of learning about
increased risk for future illness may intensify as individuals approach the typical age of
onset or show initial signs of disease.41 Investigators will need to address these issues as
they consider how to best adapt and administer questionnaires for their specific research
questions, populations, and settings.
Finally, questions remain about whether mild “negative” psychological responses might be
beneficial in some situations. Negative emotions can be powerful motivators for action when
avenues exist to reduce risks, and efforts to minimize anxiety and distress may be
counterproductive in situations in which patients would optimally engage with the
threatening information and work toward reducing their risks.42
Behavioral impact
The CSER Consortium projects are also investigating the influence of genomic sequencing
on various health behaviors. For instance, some projects are studying whether learning about
previously unknown health risks through sequencing will motivate (or demotivate)43 adults
to reduce those risks through health-promoting lifestyle changes (e.g., diet, smoking
cessation). The Consortium is also investigating effects on plans or intentions regarding
future behaviors such as those involving childbearing or insurance purchases. In addition,
there is a broad interest in information seeking (e.g., individuals' attempts to get additional
information about sequencing and results) and sharing (e.g., their disclosure of results to
other individuals). Understanding the effects of sequencing on behavioral outcomes is
important because of their potential to guide clinical adoption of sequencing and to inform
policies affecting public health and health services.
Most of the existing research has investigated these kinds of outcomes after targeted genetic
testing. Many studies have focused on changes in smoking behaviors following return of
results showing increased genetic risk for pulmonary or other diseases.44–46 Although some
positive effects have been found for smoking cessation46 and quit attempts, null results are
common. More broadly, a recent Cochrane review of research on behavioral effects of
providing genetic risk information identified effects on self-reported diet and intentions to
change behavior, but little or no effects on actual behavior change for smoking and physical
activity.47,48 Notably, the included studies were generally of poor quality and underpowered
to detect what are likely to be small effects. In addition, potential negative behavioral effects
of providing genetic risk information have not been rigorously studied. It is therefore
premature to draw conclusions about positive or negative effects of genetic risk information
—especially information from genomic sequencing—on behavioral outcomes.
Motivated by the dearth of research and the expansive scope of genomic sequencing
information, several Consortium projects are using qualitative and mixed methods to
develop a rich understanding of participants' behavioral responses to sequencing. These
approaches are well suited to discovering patterns of behaviors and their psychosocial
correlates. In addition, Consortium projects are using quantitative research methods to study
behavioral outcomes. Several institutions are using brief validated measures (e.g., the Rapid
Assessment of Physical Activity)49 as well as questions from large national studies such as
the National Cancer Institute's Health Information National Trends Survey50 or Cancer Care
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Outcomes Research and Surveillance Consortium51 or the Centers for Disease Control and
Prevention's National Health and Nutrition Examination Survey52 and Behavioral Risk
Factor Surveillance System.53 Because suitable measures did not exist for some outcomes of
interest (e.g., medication/supplement use, information sharing), many Consortium projects
have developed novel measures.
Future research would benefit from guidance from theoretical models of health decision
making or health behavior change.54 For instance, theory will be useful in determining the
circumstances under which sequencing may initiate a “teachable moment” capable of
prompting behavior change.55 The Information–Motivation–Behavioral Skills model states
that enacting certain complex behaviors requires a combination of learning information
about them, motivation to enact them, and the behavioral skills necessary for doing so.56
Thus, although genomic results may be capable of motivating behavior change (e.g., as
indicated by changes in intentions), that change may not occur if other crucial factors are
missing (e.g., skills or resources required for behavior change). Research currently under
way in the Consortium to assess barriers and facilitators of decision-making and behavior
change after testing could provide additional information about the potential for sequencing
to shape individuals' health behaviors.
Health-care resource utilization
A major question about the clinical implementation of genomic sequencing is its economic
impact on patients and on the health-care system. Multiple issues arise when sequencing
data are integrated into clinical care. First, the expected costs of data generation,
interpretation, and reporting are substantial. Second, many institutions will need to develop
or expand their infrastructures to deliver genomic-based care and to provide adequate
follow-up for a range of incidental findings. Needed resources will be highly dependent on
the clinical indication for testing and on policies and processes for return of incidental
findings. Economic resources that should be considered include (i) institutional genomic
review committees, if utilized; (ii) education and genetic counseling for patients; (iii)
education for health-care providers; (iv) evaluation of patient preferences for incidental
findings; and (v) the time required to return and discuss results with patients.
A more controversial issue is the downstream impact of genomic sequencing results on
utilization of health-care resources. Some have argued that incidental findings, false-positive
results, and results that are ambiguous could result in expensive and possibly unnecessary
tests and consultations, and also lead to increased anxiety and other possible harms.57
Projects in the CSER Consortium are studying the economic impact of genomic sequencing
in a variety of ways, primarily through measurement of health-care resource utilization
(HRU). A number of the short- and intermediate-term HRU behaviors being measured in the
CSER studies are shown in Table 1. These data can be collected using a variety of methods,
including evaluation of electronic medical records, reimbursement claims, patient surveys,
and patient diaries. Each method has strengths and weaknesses. If patients are all enrolled in
the same health-care system with electronic medical records or claims data, evaluation will
be more straightforward.58 One challenge—as with all economic evaluations—is balancing
the resources and burden of collecting these data with the value they provide. Another
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consideration is how to evaluate the longer-term HRU impact of changes in health status
resulting from interventions initiated by findings from genomic sequencing. Typically,
decision analysis models are used to estimate such broad and longer-term clinical and
economic effects.
Four challenges specific to assessing whether genomic sequencing is a justified use of
health-care resource utilization are (i) assessing the HRU of family members who may elect
to pursue genomic testing based on the index patient's findings; (ii) assessing the
tremendous diversity of potential health impacts and associated HRU changes resulting from
return of incidental findings; (iii) incorporating inherent value that patients place on
receiving findings, independent of their clinical relevance (personal utility); and (iv)
identifying appropriate comparator groups in order to access the effectiveness of changes in
care. At a minimum, investigators should consider collecting information about whether
patients have informed family members of their results. Further efforts to identify uptake of
genomic testing or other medical care services initiated by sharing of results may be
warranted but will be resource intensive. Given the variety of incidental findings that could
be returned, it will not be possible to model all potential impacts of return of incidental
findings. Approaches to assess the depth and breadth of this issue will need to be developed
based on experience with ongoing research studies. Last, although the value that patients
place on personal utility is not routinely considered in the development of clinical or
reimbursement guidelines, personal utility is a patient-centered outcome that may drive
much of genomic sequencing uptake and utilization.59 Approaches to measure personal
utility, understand its importance, and consider it in policy development are needed. As a
preliminary step in exploring personal utility, at least one project will conduct a discrete-
choice experiment that can provide estimates of the value patients place on different types of
incidental findings.60
Decision satisfaction and regret
Another area of inquiry within the CSER Consortium includes an exploration of how
individuals arrive at, and reflect upon, their decisions related to the receipt of genome
sequencing results. Elements of the decision making process include, but are not limited to,
understanding, engagement, risk perception, worries, uncertainty perceptions, response
efficacy, and attitudes toward learning results. Various scales have been used for several
decades to assess both the process and outcomes of medical decision making,61 and several
outcome scales have been used to assess the quality of decision making specifically in the
context of genetic testing. To date, much of the research in genetic testing has focused on
outcomes of decisions to undergo prenatal testing and testing for cancer risk.62–65
In most of the CSER Consortium projects, when decision making is studied, the focus is on
decision outcomes, including informed choice, decision satisfaction and/or regret, and
satisfaction with communication. Often, eligible individuals are asked to make decisions not
only about having genomic testing performed but also about the types of incidental findings
they wish to receive. Such decisions could result in learning useful, distressing, or unwanted
information that has implications not only for the person tested but also for family members.
Decision-quality assessments are key to understanding the overall value of sequencing
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results in both clinical and research contexts. A number of the projects in the CSER
Consortium are using the Decision Regret Scale to evaluate postdecision outcomes.66 It
includes five items to rate the level of remorse or distress over a treatment-related decision.
Decision regret has been shown to be negatively associated with satisfaction with the
decision-making process and positively associated with poorer health outcomes and
decisional conflict.66
Projects in the Consortium are also measuring satisfaction with physician–patient
communication and with genetic counseling.67 Although some projects have developed
novel communication satisfaction measures, others are adapting items (e.g., from the Health
Information National Trends Survey,50 the Roter Interaction Analysis System)68 or are
using validated instruments such as the general communication subscale of the Quality of
End-of-Life Communication measure.69 Due to the diversity of communication systems and
genomic decision support in the CSER projects, some projects also aim to assess individuals'
satisfaction with the usability of computer systems employed in the course of genomic
sequencing.70,71 In addition, a number of sites are creating novel measures to evaluate
individuals' satisfaction with testing and items that aim to capture whether genomic
sequencing meets their expectations.
Assessments of decision quality are likely to be related to other process and outcome
variables that are being measured by most of the CSER projects. For example, several
projects are assessing the process and/or content of informed consent or return of results, as
well as psychosocial outcomes of genomic sequencing, such as quality of life, anxiety,
multidimensional impact, and coping. The quality of the decision is likely to be predictive of
these types of outcome measures as well.
Discussion
In addition to identifying core domains for coordination, our Working Group has discussed a
number of methodological and conceptual issues that are likely to transcend individual
projects. As noted previously, because the landscape of genomic sequencing is
underexplored, complementary qualitative and quantitative research methods may be needed
to capture the breadth and depth of people's experiences with sequencing. Such mixed-
methods approaches are likely to yield the most comprehensive understanding of impact.
Second, there may be significant differences, both in terms of impact and in terms of the
assessment of impact, when sequencing is performed in a clinical versus a research context.
For example, obligations related to the return of incidental findings or the requirements for
informed consent might differ depending on whether sequencing is performed for clinical or
research purposes. Third, practical, normative, and ethical factors may influence decisions
about whether or not to elicit individuals' preferences for genomic test result disclosure, and
decisions about preference elicitation are likely to influence impact. Finally, when assessing
the impact of genomic sequencing on individuals, it is important to note that there are likely
to be interactions between individual, health-care system, and social context characteristics,
and outcomes. Accurate measurement of important covariates will be essential if we are to
understand the ways in which the impact of sequencing varies across different populations
and settings.
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Although the CSER Consortium Outcomes and Measures working group has identified a
number of domains as high priority for investigation, we readily acknowledge that rapid
advances in genome science create a dynamic environment in which the implications of
testing will evolve. Behavioral and social scientists, legal and ethics scholars, clinical
investigators, and clinicians will need to coevolve with genome scientists in order to ensure
that their work continually addresses core genomic questions. Continued efforts to
coordinate sequencing-related research activities across sites and disciplines will aid in our
understanding of individuals' experiences with genomic sequencing and help to establish
best practices for sequencing programs of the future.
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Figure 1. The process and potential outcomes of genomic sequencing
Dark boxes are outcomes that are featured in this article. Gray boxes represent steps in the
clinical process.
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Table 1
Outcome measures coordinated across CSER sites by domain
Selected outcomes included in CSER projectsa
Preferences
 Preferred role of patient in medical decision making7
 Novel preference measures under development by CSER sites
  Elicitation of sequencing-related preferences through hypothetical vignettes
  Elicitation of actual preferences for the disclosure of incidental information
  Elicitation of preferences for the integration of sequencing results in medical records
Understanding
 Knowledge about genetics and genome sequencing16
 Novel understanding measures under development by CSER sites
  Understanding of sequencing-related informed consent concepts
  Comprehension of the implications of sequencing findings
  Recall of sequencing results disclosed
  Perceptions of uncertainty related to sequence information
Psychosocial impact
 Anxiety and depression28–30,72
 Multidimensional impact34,35
Behavioral impact
 Information seeking & sharing73, 74
  Health information engagement and apprehension
  Communication of sequencing findings to family members
  Novel information seeking and sharing measures under development by CSER sites
 Health behavior
  Physical activity
  Fruit and vegetable consumption
  Smoking
 Novel behavior measures under development by CSER sites (examples)
  Changes in medical treatment
  Vitamin, supplement, and medication use
  Increased/decreased motivation to enact a variety of health-related behaviors
Health-care utilization
 Hospital utilization and access to care52
 Novel health-care utilization measures under development by CSER sites (examples)
  Medical care visits (e.g., general practitioner, medical specialist, genetics provider)
  Hospital-based care (e.g., acute care, planned care)
  Medical tests/procedures (e.g., screening, diagnostic, surveillance)
  Medication changes (e.g., prescription, over the counter)
  Insurance (e.g., health, life, disability, long-term care)
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Selected outcomes included in CSER projectsa
  Health behavior programs (e.g., smoking cessation)
Decisional satisfaction & regret
 Decision regret66
 Decisional conflict75
 Novel decision satisfaction and regret measures under development by CSER sites
  Satisfaction with communication of sequencing results
  Satisfaction with sequencing results
  Sequencing-related expectations satisfied
CSER, Clinical Sequencing Exploratory Research Consortium.
a
Only measures that are utilized by two or more sites in the consortium are referenced. Citations do not provide a complete list of measures
available for these domains, nor are they intended to be an endorsement of particular measures as the optimal measures in that domain.
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